# Qualigen Therapeutics Inc. (QLGN)

Source: https://www.quantisnow.com/company/QLGN
Generated: 2026-11-11T11:38:30.687Z

- Ticker: QLGN
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2015
- Website: qualigeninc.com

## About

Qualigen, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system; ALAN, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; AS1411 for treating viral-based infectious diseases; RAS-F3, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen, Inc. was founded in 1996 and is based in Carlsbad, California.

## Latest QLGN news and filings

- 2025-11-21 21:30 UTC [SEC Form 8-K] [SEC Form 8-K filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-qualigen-therapeutics-inc-6290409)
- 2025-11-21 21:23 UTC [SEC Form 8-K] [Qualigen Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/qualigen-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6290351)
- 2025-11-20 22:10 UTC [SEC Form 8-K] [SEC Form 8-K filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-qualigen-therapeutics-inc-6289216)
- 2025-11-19 22:17 UTC [Amendment: SEC Form SCHEDULE 13D/A filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13da-filed-by-qualigen-therapeutics-inc-6287453)
- 2025-11-17 11:10 UTC [SEC Form 8-K] [Qualigen Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Other Events](https://www.quantisnow.com/insight/qualigen-therapeutics-inc-filed-sec-form-8-k-amendments-to-articles-6281902)
- 2025-11-16 21:10 UTC [Qualigen Therapeutics Stockholders Approve All Proposals with Majority Vote; Company to Rebrand as AIxCrypto Holdings, Inc. (Nasdaq: AIXC) Following November 20 Nasdaq Ceremony and Announces Transition into AI × Web3 Strategy](https://www.quantisnow.com/insight/qualigen-therapeutics-stockholders-approve-all-proposals-with-majority-vote-company-6281738)
- 2025-11-14 22:16 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-qualigen-therapeutics-inc-6281427)
- 2025-11-12 22:17 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-qualigen-therapeutics-inc-6275430)
- 2025-10-28 03:57 UTC [Qualigen Therapeutics to Rebrand as AIxCrypto After Stockholder Meeting on November 12, with Three Core Goals for 2025](https://www.quantisnow.com/insight/qualigen-therapeutics-to-rebrand-as-aixcrypto-after-stockholder-meeting-on-6246587)
- 2025-10-23 20:05 UTC [Qualigen Therapeutics Partners with BitGo to Execute First Multi-Asset C10 Treasury Allocation](https://www.quantisnow.com/insight/qualigen-therapeutics-partners-with-bitgo-to-execute-first-multi-asset-c10-6243278)
- 2025-10-20 21:20 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-qualigen-therapeutics-inc-6238917)
- 2025-10-13 01:00 UTC [Qualigen Therapeutics Announces the Official Launch of C10 Cryptocurrency Asset Treasury (DAT) Purchases: Why Is This Pullback the Golden Moment CXC10 Has Been Waiting For?](https://www.quantisnow.com/insight/qualigen-therapeutics-announces-the-official-launch-of-c10-cryptocurrency-asset-6230481)
- 2025-10-10 21:15 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-qualigen-therapeutics-inc-6230270)
- 2025-10-07 00:07 UTC [SEC Form 8-K] [SEC Form 8-K filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-8-k-filed-by-qualigen-therapeutics-inc-6225286)
- 2025-10-03 21:27 UTC [SEC Form 8-K] [Qualigen Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/qualigen-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6223294)
- 2025-09-30 20:00 UTC [Public Offering] [Univest Securities, LLC Announces Closing of $41 Million Strategic Investment in Client Qualigen Therapeutics (NASDAQ: QLGN) from Client Faraday Future (NASDAQ: FFAI)](https://www.quantisnow.com/insight/univest-securities-llc-announces-closing-of-41-million-strategic-investment-6215936)
- 2025-09-30 11:08 UTC [Qualigen Therapeutics Announces Successful Closing of $41 Million PIPE Financing Led by Faraday Future, Accelerating New Business Transformation into Crypto](https://www.quantisnow.com/insight/qualigen-therapeutics-announces-successful-closing-of-41-million-pipe-financing-6215238)
- 2025-09-30 10:00 UTC [Public Offering] [Faraday Future Announces Closing of Strategic $41 Million Investment in Qualigen Therapeutics (NASDAQ: QLGN) to Accelerate its Dual-Flywheel & Dual-Bridge Eco Strategy](https://www.quantisnow.com/insight/faraday-future-announces-closing-of-strategic-41-million-investment-in-6215025)
- 2025-09-29 10:04 UTC [SEC Form 8-K] [Qualigen Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/qualigen-therapeutics-inc-filed-sec-form-8-k-leadership-update-financial-6213651)
- 2025-09-29 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-qualigen-therapeutics-inc-6213649)
- 2025-09-25 21:05 UTC [SEC Form 8-K] [Qualigen Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/qualigen-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6212213)
- 2025-09-24 20:28 UTC [SEC Form RW filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-rw-filed-by-qualigen-therapeutics-inc-6210718)
- 2025-09-22 00:00 UTC [Faraday Future Announced a Total Strategic Investment of $41 million in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) During its Annual 919 Event, for its Crypto Business Focusing on Three Growth Engines](https://www.quantisnow.com/insight/faraday-future-announced-a-total-strategic-investment-of-41-million-6207232)
- 2025-09-19 23:24 UTC [Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) for Crypto Business Through PIPE Transaction](https://www.quantisnow.com/insight/faraday-future-announces-strategic-41-million-investment-in-qualigen-therapeutics-6207190)
- 2025-09-19 22:01 UTC [Faraday Future Announces Strategic $41 Million Investment in Qualigen Therapeutics, Inc. (NASDAQ: QLGN) f for Crypto Business Through PIPE Transaction](https://www.quantisnow.com/insight/faraday-future-announces-strategic-41-million-investment-in-qualigen-therapeutics-6207157)
- 2025-09-16 20:33 UTC [SEC Form S-1] [SEC Form S-1 filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-s-1-filed-by-qualigen-therapeutics-inc-6202666)
- 2025-09-16 13:46 UTC [SEC Form 8-K] [Qualigen Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits](https://www.quantisnow.com/insight/qualigen-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6202113)
- 2025-09-08 20:30 UTC [SEC Form 8-K] [Qualigen Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing](https://www.quantisnow.com/insight/qualigen-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-6193499)
- 2025-08-27 20:30 UTC [SEC Form 8-K] [Qualigen Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/qualigen-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6181004)
- 2025-08-14 21:29 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-qualigen-therapeutics-inc-6167219)
- 2025-08-13 21:05 UTC [SEC Form D] [SEC Form D filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-qualigen-therapeutics-inc-6163670)
- 2025-08-07 13:48 UTC [Amendment: SEC Form SCHEDULE 13G/A filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/amendment-sec-form-schedule-13ga-filed-by-qualigen-therapeutics-inc-6152877)
- 2025-07-28 21:29 UTC [SEC Form 8-K] [Qualigen Therapeutics Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/qualigen-therapeutics-inc-filed-sec-form-8-k-notice-of-delisting-6134856)
- 2025-07-28 21:20 UTC [Qualigen Therapeutics Provides Update on Nasdaq Communications and Continued Listing Status](https://www.quantisnow.com/insight/qualigen-therapeutics-provides-update-on-nasdaq-communications-and-continued-listing-6134825)
- 2025-07-28 20:58 UTC [SEC Form 8-K] [Qualigen Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/qualigen-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6134677)
- 2025-07-28 16:41 UTC [Qualigen Therapeutics Announces $4.5 Million Private Placement of Series A-3 Convertible Preferred Stock](https://www.quantisnow.com/insight/qualigen-therapeutics-announces-45-million-private-placement-of-series-a-3-6134138)
- 2025-07-21 21:27 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-qualigen-therapeutics-inc-6127118)
- 2025-07-16 13:28 UTC [SEC Form 8-K] [Qualigen Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/qualigen-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6121676)
- 2025-07-16 12:00 UTC [Qualigen Granted New Patents Covering 25 Countries](https://www.quantisnow.com/insight/qualigen-granted-new-patents-covering-25-countries-6121426)
- 2025-06-30 21:28 UTC [SEC Form 10-K] [SEC Form 10-K filed by Qualigen Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-qualigen-therapeutics-inc-6104258)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/QLGN
- Earnings history: https://www.quantisnow.com/earnings/QLGN
- Dividend history: https://www.quantisnow.com/dividends/QLGN
- Insider transactions: https://www.quantisnow.com/insiders/QLGN
- Options chain: https://www.quantisnow.com/options/QLGN
- SEC 8-K filings only: https://www.quantisnow.com/company/QLGN/8-k
- RSS and alerts for QLGN: https://www.quantisnow.com/docs/rss-feeds.md